Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.creatorGallego-Martínez, A. (Alejandro)-
dc.creatorGarrido, D. (Diego)-
dc.creatorYébenes, L. (Laura)-
dc.creatorMendiola, M. (Marta)-
dc.creatorCastelo, B. (Beatriz)-
dc.creatorRedondo, A. (Andrés)-
dc.date.accessioned2024-02-09T15:38:25Z-
dc.date.available2024-02-09T15:38:25Z-
dc.date.issued2021-
dc.identifier.citationGallego-Martínez, A. (Alejandro); Garrido, D. (Diego); Yébenes, L. (Laura); et al. "Long-term response to olaparib in BRCA1-related ovarian cancer with brain metastases". metastasesInternational Journal of Gynecologic Cancer. 31 (9), 2021, 1292 - 1296es_ES
dc.identifier.urihttps://hdl.handle.net/10171/69017-
dc.description.abstractA 51-year-old woman with an unremarkable personal and family medical history sought medical attention after noticing an abdominal mass, which was located mainly in the right iliac fossa. A gynecological ultrasound and a CT body scan showed a 22.3×11.5 cm pelvic mass dependent on both ovaries, with peritoneal implants, retroperitoneal lymph nodes, and ascites, without supra-diaphragmatic disease, associated with a serum CA125 level of 2634 kIU/L. The patient first underwent an exploratory laparoscopy, and later a complete cytoreduction was performed with hysterectomy, bilateral salpingo-oophorectomy, omentectomy, appendectomy, pelvic and para-aortic lymphadenectomy, and resection of tumor implants and the transverse, descending, and sigmoid colon. The histopathological examination confirmed the diagnosis of International Federation of Gynecology and Obstetrics (FIGO) stage IIIC high-grade serous ovarian carcinoma (Figure 1). After primary cytoreduction, the patient received six cycles of carboplatin, area under the curve 6 mg/mL/min, and paclitaxel 175 mg/m2 every 3 weeks. At the end of the treatment no disease remained on the CT scan and the CA125 level was normal.es_ES
dc.language.isoenges_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectBRCA1-related ovarian canceres_ES
dc.subjectCT bodyes_ES
dc.subjectCA125es_ES
dc.subjectInternational Federation of Gynecology and Obstetrics (FIGO)es_ES
dc.subjectIIIC high-grade serous ovarian carcinomaes_ES
dc.titleLong-term response to olaparib in BRCA1-related ovarian cancer with brain metastaseses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://ijgc.bmj.com/content/31/9/1292.infoes_ES
dc.editorial.note© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.es_ES
dadun.citation.endingPage1296es_ES
dadun.citation.number9es_ES
dadun.citation.publicationNamemetastasesInternational Journal of Gynecologic Canceres_ES
dadun.citation.startingPage1292es_ES
dadun.citation.volume31es_ES

Ficheros en este ítem:
Vista previa
Fichero
OLAPARIB OVARIAN CANCER BRAIN METASTASES.pdf
Descripción
Tamaño
1.42 MB
Formato
Adobe PDF


Estadísticas e impacto
0 citas en
0 citas en

Los ítems de Dadun están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.